IDEXX Laboratories Publishes Investor Presentation on Innovation-Driven Veterinary Diagnostics Growth and Software, Data and AI Enablement

Reuters

Mar 02

IDEXX Laboratories Publishes Investor Presentation on Innovation-Driven Veterinary Diagnostics Growth and Software, Data and AI Enablement

IDEXX Laboratories Inc. outlined its innovation-driven growth strategy at the Raymond James 47th Annual Institutional Investors Conference, highlighting a global veterinary testing opportunity tied to a 45 billion dollar-plus total addressable market in veterinary medical services. The company emphasized new point-of-care platforms and expansion into disease areas including oncology, along with leveraging its installed base through menu extensions, vertical SaaS and AI enablement, and increased international commercial reach. IDEXX also discussed the IDEXX Cancer Dx platform, including performance metrics for canine lymphoma and mast cell tumors, and described plans to broaden cancer screening as part of preventive care panels for at-risk dogs. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2616356333"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616356333\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616356333?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616356333","market":"fut","top_or_hot":-1,"title":"IDEXX Laboratories Publishes Investor Presentation on Innovation-Driven Veterinary Diagnostics Growth and Software, Data and AI Enablement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IDEXX Laboratories Publishes Investor Presentation on Innovation-Driven Veterinary Diagnostics Growth and Software, Data and AI Enablement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IDEXX Laboratories Inc. outlined its innovation-driven growth strategy at the Raymond James 47th Annual Institutional Investors Conference, highlighting a global veterinary testing opportunity tied to a 45 billion dollar-plus total addressable market in veterinary medical services. The company emphasized new point-of-care platforms and expansion into disease areas including oncology, along with leveraging its installed base through menu extensions, vertical SaaS and AI enablement, and increased international commercial reach. IDEXX also discussed the IDEXX Cancer Dx platform, including performance metrics for canine lymphoma and mast cell tumors, and described plans to broaden cancer screening as part of preventive care panels for at-risk dogs. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IDEXX Laboratories Publishes Investor Presentation on Innovation-Driven Veterinary Diagnostics Growth and Software, Data and AI Enablement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIDEXX Laboratories Publishes Investor Presentation on Innovation-Driven Veterinary Diagnostics Growth and Software, Data and AI Enablement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-02 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IDEXX Laboratories Publishes Investor Presentation on Innovation-Driven Veterinary Diagnostics Growth and Software, Data and AI Enablement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IDEXX Laboratories Inc. outlined its innovation-driven growth strategy at the Raymond James 47th Annual Institutional Investors Conference, highlighting a global veterinary testing opportunity tied to a 45 billion dollar-plus total addressable market in veterinary medical services. The company emphasized new point-of-care platforms and expansion into disease areas including oncology, along with leveraging its installed base through menu extensions, vertical SaaS and AI enablement, and increased international commercial reach. IDEXX also discussed the IDEXX Cancer Dx platform, including performance metrics for canine lymphoma and mast cell tumors, and described plans to broaden cancer screening as part of preventive care panels for at-risk dogs. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0690374615.EUR","symbol_name":"FUNDSMITH EQUITY \"R\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL9yHjKM:1","article_id":"2616356333","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616356333","pubTimestamp":1772463743,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IDEXX Laboratories Publishes Investor Presentation on Innovation-Driven Veterinary Diagnostics Growth and Software, Data and AI Enablement. IDEXX Laboratories Inc. outlined its innovation-driven growth strategy at the Raymond James 47th Annual Institutional Investors Conference, highlighting a global veterinary testing opportunity tied to a 45 billion dollar-plus total addressable market in veterinary medical services. The company emphasized new point-of-care platforms and expansion into disease areas including oncology, along with leveraging its installed base through menu extensions, vertical SaaS and AI enablement, and increased international commercial reach. IDEXX also discussed the IDEXX Cancer Dx platform, including performance metrics for canine lymphoma and mast cell tumors, and described plans to broaden cancer screening as part of preventive care panels for at-risk dogs. You can access the full presentation through the link below.Disclaimer: This news brief was created by Pu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","IDXX":"爱德士实验室","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","BK4082":"医疗保健设备","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4504":"桥水持仓","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","BK4588":"碎股"},"translate_title":"IDEXX Laboratories发布关于创新驱动的兽医诊断增长以及软件、数据和人工智能支持的投资者演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDXX":0.9},"content_text":"IDEXX Laboratories Publishes Investor Presentation on Innovation-Driven Veterinary Diagnostics Growth and Software, Data and AI Enablement\n    \n\n        IDEXX Laboratories Inc. outlined its innovation-driven growth strategy at the Raymond James 47th Annual Institutional Investors Conference, highlighting a global veterinary testing opportunity tied to a 45 billion dollar-plus total addressable market in veterinary medical services. The company emphasized new point-of-care platforms and expansion into disease areas including oncology, along with leveraging its installed base through menu extensions, vertical SaaS and AI enablement, and increased international commercial reach. IDEXX also discussed the IDEXX Cancer Dx platform, including performance metrics for canine lymphoma and mast cell tumors, and described plans to broaden cancer screening as part of preventive care panels for at-risk dogs. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}